Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
A recently recognized variant of chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) expressing somatic hypermutations of the Immunoglobulin heavy chain (IGH) genes. The recognition of this variant alters the belief that CLL/SLL is always derived from a naive, pregerminal center B-cell. The presence of somatic hypermutations of IGH genes occurs in approximately 50% of CLL/SLL cases and implies a postgerminal center, memory origin. Patients with this variant of CLL/SLL have a favorable prognosis, with a reported median survival of more than 24 years.
Biomarker and diagnostic research for chronic lymphocytic leukemia/small lymphocytic lymphoma with immunoglobulin heavy chain variable-region gene somatic hypermutation has been reported in the published literature.
1 FDA-approved treatment is available for chronic lymphocytic leukemia/small lymphocytic lymphoma with immunoglobulin heavy chain variable-region gene somatic hypermutation, including BENDAMUSTINE HYDROCHLORIDE (BENDAMUSTINE HYDROCHLORIDE, approved 2022).
Brand Name | Generic Name | Mechanism | Approved |
|---|
No clinical trials have been registered for chronic lymphocytic leukemia/small lymphocytic lymphoma with immunoglobulin heavy chain variable-region gene somatic hypermutation.
10 publications have been identified in PubMed for chronic lymphocytic leukemia/small lymphocytic lymphoma with immunoglobulin heavy chain variable-region gene somatic hypermutation. Research spans Basic Science / Preclinical (40%), Diagnostic / Biomarker (30%), and Review / Meta-Analysis (10%).
Research Type | Count | % of Total |
|---|---|---|
Laboratory research | 4 |
Data assembled from 3 of 12 sources · Last updated Sep 21, 2026, 2:31 PM UTC
Program availability and eligibility requirements are set by each foundation. Contact them directly to learn more about your options.
Claim this page and your organization will be listed here for patients and families to find.
BENDAMUSTINE HYDROCHLORIDE | BENDAMUSTINE HYDROCHLORIDE | — | 2022 | Available |
View trials for chronic lymphocytic leukemia/small lymphocytic lymphoma with immunoglobulin heavy chain variable-region gene somatic hypermutation
40%
Testing and diagnosis research | 3 | 30% |
Research summaries | 1 | 10% |
Patient case studies | 1 | 10% |
Clinical study results | 1 | 10% |
Chakraborty SR (2026). [PMID: 41595525](https://pubmed.ncbi.nlm.nih.gov/41595525/). *Genes*. [Basic Science / Preclinical]
Lee T (2026). [PMID: 41024698](https://pubmed.ncbi.nlm.nih.gov/41024698/). *Annals of laboratory medicine*. [Basic Science / Preclinical]
Dampmann M (2025). [PMID: 40493712](https://pubmed.ncbi.nlm.nih.gov/40493712/). *Leukemia & lymphoma*. [Basic Science / Preclinical]
Wojtaszewska M (2025). [PMID: 40998002](https://pubmed.ncbi.nlm.nih.gov/40998002/). *The Journal of molecular diagnostics : JMD*. [Diagnostic / Biomarker]
Nabki J (2025). [PMID: 39690182](https://pubmed.ncbi.nlm.nih.gov/39690182/). *Leukemia*. [Clinical Trial Publication]
Sabatini P (2025). [PMID: 40734655](https://pubmed.ncbi.nlm.nih.gov/40734655/). *American journal of clinical pathology*. [Diagnostic / Biomarker]
Wood RK (2025). [PMID: 41157957](https://pubmed.ncbi.nlm.nih.gov/41157957/). *International journal of laboratory hematology*. [Review / Meta-Analysis]
Castonguay M (2025). [PMID: 41149470](https://pubmed.ncbi.nlm.nih.gov/41149470/). *Curr Oncol*. [Case Report / Case Series]
Gao MG (2025). [PMID: 41145284](https://pubmed.ncbi.nlm.nih.gov/41145284/). *Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi*. [Basic Science / Preclinical]
Pott C (2025). [PMID: 39424725](https://pubmed.ncbi.nlm.nih.gov/39424725/). *Methods Mol Biol*. [Diagnostic / Biomarker]